EUFEST STUDY PDF

The European First Episode Schizophrenia Trial (EUFEST): Comparison of outcome in The European study of the effectiveness of haloperidol, amisulpride . The study helps solve the question of which category of antipsychotic medications best address impaired cognition, which affects a significant. The EUFEST study then undertook with a pragmatic open randomized-controlled trial design to compare the effectiveness of second-generation antipsychotic.

Author: Zulkimi Nit
Country: South Africa
Language: English (Spanish)
Genre: Travel
Published (Last): 25 October 2018
Pages: 252
PDF File Size: 12.76 Mb
ePub File Size: 4.80 Mb
ISBN: 589-9-72398-294-8
Downloads: 23142
Price: Free* [*Free Regsitration Required]
Uploader: Tern

What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder? We focus on the real world treatment of first stufy patients by enrolling heterogeneous patient populations, including patients who show comorbid drug abuse or who are aggressive or suicidal or less likely to be compliant with treatment.

Loss of retention can be the result of insufficient clinical effect, or lack of tolerability or stuyd. Previous Trial Back to results Next Trial. At regular time intervals patients are followed-up until 12 months after recruitment: Quality of life 6.

Natural history of schizophrenia. PfizerAstraZenecaSanofi-Aventis.

Home Who eeufest we? Ethics approval Ethics approval received from the local medical ethics committee Study design Multicentre, randomised active controlled, parallel group trial Primary study design Interventional Secondary study design Randomised controlled trial Trial setting Hospitals Trial type Treatment Patient information sheet Condition Schizophrenia, schizophreniform, or schizoaffective disorder Intervention Drug: Second-generation antipsychotic drugs were introduced over a decade ago studj the treatment of schizophrenia; however, their purported clinical effectiveness compared with first-generation antipsychotic drugs is still debated.

  BROWNSVILLE TEBRA PDF

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

Diagnosis of schizophrenia, schizophreniform or schizoaffective disorder 2. SchizophreniaSchizophreniform disorderSchizoaffective disorder. The presence of one or more of the contraindications against any of the study drugs. The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia.

Secondary measures include changes in different dimensions of psychopathology, side effects, compliance, social needs, quality of life, substance abuse and cognitive functions. The primary outcome measure was all-cause treatment discontinuation. Diagnosis of schizophrenia; 2.

Amisulpride, Haloperidol, Olanzapine, Quetiapine, Ziprasidone. Comparisons with haloperidol showed lower risks for any-cause discontinuation with amisulpride hazard ratio [HR] 0.

Eligibility Participant inclusion criteria 1. Study information Scientific title The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia Acronym EUFEST Study hypothesis What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder?

Secondary outcome measures At regular time intervals patients are followed-up until 12 months after recruitment: This pragmatic trial suggests that clinically meaningful antipsychotic treatment of first-episode of schizophrenia is achievable, for at least 1 year.

Plain English Summary Not provided at time of registration Trial eufesy http: However, we cannot conclude that second-generation drugs are more efficacious than is haloperidol, since discontinuation rates are not necessarily consistent with symptomatic improvement.

Euest outcome is assessed eufewt regular time intervals until 12 months after recruitment.

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

At regular time intervals patients are followed-up until 12 months after recruitment: The presence of one or more sutdy the eufets against any of the study drugs. Intolerance to one of the drugs in this study 4. Schizophreniform or schizoaffective disorder; 3. Rationale and design of the trial. At present, more than patients have been recruited and randomized in the eufesg countries: Retention to sutdy study drug, which is the time that the patient stays on the randomised stjdy within the study dose range.

  BRAMANTI PAGANI SALSA MATEMATICA CALCOLO INFINITESIMALE E ALGEBRA LINEARE PDF

Analysis was by intention to treat. The primary outcome measure is retention in treatment, defined as time to discontinuation of study drug.

The principal investigators are Prof. Results and Publications Publication and dissemination plan Not provided at time of registration Intention to publish date Participant level data Not provided at time of registration Basic results scientific Publication list 1.

Most studies comparing second generation antipsychotics with classical neuroleptics have been conducted in more or less chronic schizophrenia patients. These and other facts have stimulated discussions regarding the effectiveness of the new generation of antipsychotics. Such studies were usually conducted in highly selected samples, and were generally designed and financed by the manufacturer of the drug tested.

Genetic determinants of response to antipsychotic drugs 9. EUFEST assesses the effectiveness of a low dose of haloperidol versus regular doses of 4 second generation antipsychotics: Comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens.

Intolerance to one of the drugs in this study; 4. The Lancet ;